Pharmaceutical giant GlaxoSmithKline inked a deal with Carlsbad-based Regulus Therapeutics LLC valued at up to $600 million to develop new microRNA drugs that target inflammatory disease, the companies said April 17...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99